Chronic hand eczema (CHE) significantly impairs workplace productivity and academic performance, with recent clinical data indicating that nearly one in four adults with severe symptoms reported taking sick leave in the past year. According to findings from the DELTA FORCE and DELTA TEEN Phase 3 studies presented at the 2026 European Society of Contact Dermatitis (ESCD) Congress, patients face persistent barriers to daily functioning that current standard-of-care treatments often fail to address.
How Does Chronic Hand Eczema Impact Workforce Productivity?
The economic and professional burden of severe CHE is substantial. Data from the DELTA FORCE study show that approximately 25% of adults with the condition required sick leave over a 12-month period. Beyond absenteeism, nearly 30% of participants reported that their symptoms worsened while performing job-related tasks, according to the study findings.
Lead author Andrea Bauer, MD, MPH, of the University Hospital Carl Gustav Carus Dresden, describes CHE as a major societal challenge rather than a simple dermatological issue. She notes that when individuals cannot maintain productivity, the consequences ripple outward to employers and the broader economy. The study suggests that shifting treatment strategies toward therapies that improve both symptom management and functional capacity is essential for workforce stability.
Treatment Efficacy: Comparing Therapeutic Outcomes
Clinical trials have begun to differentiate between treatment options based on patient-reported outcomes. In the DELTA FORCE study, patients treated with topical delgocitinib (Anzupgo) reported higher levels of improvement in daily activities and work productivity compared to those receiving oral alitretinoin. These functional gains were correlated with higher scores across quality-of-life assessments, according to the study data.
What Are the Long-Term Effects on Adolescent Development?
For adolescents, the impact of moderate-to-severe CHE extends beyond physical discomfort. Research published in The Lancet Child & Adolescent Health highlights how the condition interferes with school attendance, academic participation, and the development of daily routines during a critical life stage. The DELTA TEEN study indicates that standard treatments currently available for this demographic have shown limited success in mitigating these academic and social disruptions.
Frequently Asked Questions
Why is chronic hand eczema considered a “societal challenge”?
According to Dr. Andrea Bauer, the condition is categorized as such because the hands are essential for nearly all daily tasks. When patients cannot use their hands effectively, it leads to lost work hours and reduced productivity, which affects employers and the economy at large.
How do researchers measure the impact of CHE on daily life?
Researchers utilize validated patient-reported outcome measures, including the Dermatology Life Quality Index (DLQI), the EQ-5D-5L for general health, and the Hand Eczema Impact Scale (HEIS), which is specifically designed to capture the unique challenges of this condition.
Is there a difference in effectiveness between current treatments?
The DELTA FORCE study demonstrated that topical delgocitinib resulted in greater improvements in self-rated work productivity and quality-of-life scores when compared to oral alitretinoin in adult patients with severe CHE.
Are you or a family member managing chronic hand eczema? Share your experience with workplace or school accommodations in the comments below, or subscribe to our newsletter for the latest updates on dermatological research and treatment breakthroughs.